Thank you. for supporting this program. For additional CME offerings, please visit
|
|
- Derrick Mitchell
- 5 years ago
- Views:
Transcription
1
2 Thank you for supporting this program For additional CME offerings, please visit
3 Accredited by: Disease Burden
4 Patient Discharges with Cirrhosis* Hospital Discharges Associated with Cirrhosis are Increasing % , , , , , , ` *ICD-9-CM codes 571.2, 571.5, and 571.6, all listed diagnoses Healthcare Cost and Utilization Project, US Department of Health and Human Services. Available at Accessed 04/24/12.
5 Complications of Cirrhosis: Focus on Hepatic Encephalopathy Primary complications include: Ascites Jaundice Variceal hemorrhage Hepatic encephalopathy Other complications that can occur include: Spontaneous bacterial peritonitis Hepatic hydrothorax Hepatorenal syndrome Portopulmonary hypertension Hepatocellular carcinoma Portal vein thrombosis Lefton HB et al. Med Clin N Am 2009;93:
6 Patient Discharges Increased Hospital Discharges Associated with HE Parallel Those of Cirrhosis Cirrhosis* HE , , , , , , , , , , , , ` *ICD-9-CM codes 571.2,571.5, and 571.6, all listed diagnoses ICD-9-CM codes 291.2, , and 472.2, all listed diagnoses Healthcare Cost and Utilization Project, US Department of Health and Human Services. Available at Accessed 04/24/12.
7 Prevalence of HE: Two Forms are Recognized Covert hepatic encephalopathy (CHE) affects approximately 20% to 60% of patients with liver disease 2 Has been called subclinical encephalopathy or minimal encephalopathy (MHE) in the past 3 International Society for Hepatic Encephalopathy and Nitrogen Metabolism has recently endorsed using the term covert encephalopathy 3 Overt hepatic encephalopathy (OHE) occurs in: 30% to 45% of cirrhotic patients 2 10% to 50% of patients with TIPS 2 TIPS = transjugular intrahepatic portosystemic shunt. 1 Mullen KD, et al. Semin Liver Dis. 2007;27(Suppl 2): Poordad FF. Aliment Pharmacol Ther. 2006;25(Suppl 1): Mullen KD, Prakash RK. Clin Liver Dis 2012;16:91-93,
8 Characterization of HE Stages Overt HE Stages Normal Covert HE I II III IV coma Categorization is often arbitrary and varies between raters Simple Clinical Diagnosis Worsening cognitive dysfunction Bajaj JS, et al. Hepatology. 2009;50:
9 Diagnosis of Covert HE Patients with covert HE have no clinical signs and symptoms of overt HE The diagnosis of covert HE is only possible through specialized psychometric and neurological measures No consensus on diagnostic criteria or diagnostic tests has been established Bajaj JS et al. Hepatology 2009;50: Mullen KD. Aliment Pharmacol Ther 2006;25(suppl 1):11-16.
10 Diagnostic Methods for Detecting Covert HE Methods Advantages Limitations Formal neuropsychological assessment Established and well-recognized clinical significance Expensive Time-consuming Short neuropsychological batteries Easy to administer in office setting Inexpensive Rapid results High sensitivity for discerning MHE from other encephalopathies Test often copyrighted Limited access Computerized tests (CFF, ICT, reaction times, etc.) Easy to apply Limited data on diagnostic significance Require standardization Neurophysiologic tests (EEG, spectral EEG, P300) Allows for objective repeat testing Equipment Limited data on diagnostic significance CFF = critical flicker frequency; ICT = inhibitory control test; P300 = auditory event-related evoked potential. Adapted from: Mullen KD, et al. Semin Liver Dis. 2007;27(Suppl 2):32-47.
11 Diagnosis of Overt HE Clinical recognition of the distinctive neurologic features of HE Knowledge that underlying cirrhosis is present Exclusion of all other etiologies of neurologic and/or metabolic abnormalities Identification of precipitating factors Severity can be measured using West Haven Criteria Adapted from Mullen KD. Semin Liver Dis. 2007;27(suppl 2):3-9.
12 West Haven Criteria for Grading Mental State in Patients With Cirrhosis Grade Features 0 No abnormalities detected I II III IV Trivial lack of awareness Euphoria or anxiety Shortened attention span Impairment of addition or subtraction Lethargy or apathy Disorientation for time Obvious personality change Inappropriate behavior Somnolence to semi-stupor Responsive to stimuli Confused Gross disorientation Bizarre behavior Coma, unable to test mental state Bajaj JS, et al. Aliment Pharmacol Ther. 2011;33:
13 Hepatic Encephalopathy: Pathophysiology HE pathogenesis appears to be multifactorial and involves: An increase in nitrogenous substances in the systemic circulation, derived from production in the gut Cerebral edema, due to uptake of ammonia into astrocytes where it is combined with intracellular glutamate Oxidative stress Inflammatory mediators Adapted from Mullen KD et al. Semin Liver Dis. 2007;27(suppl 2):32-47.
14 Consequences of Covert HE Increased progression to OHE: >50% develop overt HE within 30 months 1 Significantly diminishes quality of life 2 Significantly diminishes working and earning capacity in blue-collar workers 2 Impairs driving on structured driving tests 3,4 Increases risk of traffic accidents and violations 5 1. Hartmann IJ, et al. Am J Gastroenterol. 2000;95(8): Groeneweg M, et al. Hepatology. 1998;28(1): Wein C, et al. Hepatology. 2004;39(3): Watanabe A, et al. Metab Brain Dis. 1995;10(3): Bajaj JS, et al. Am J Gastroenterol. 2007;102(9):
15 Development of clinical HE Probability of OHE in Patients With and Without MHE (25) (91) (21) (88) (20) P <.001 MHE positive (11) MHE negative (84) Months Adapted from: Hartmann IJ, et al. Am J Gastroenterol. 2000;95(8):
16 Survival, % Overt HE is Associated with a Poor Prognosis <50% survival at 1 year after diagnosis of HE; <25% survival at 3 years % survival at 1 year 23% survival at 3 years Months Bustamante et al. J Hepatol. 1999;30:
17 ICU and One Year Mortality of Patients with Severe HE Isolated HE* (n=45) Other HE Patients (n=26) p Glasgow Coma Scale at Admission Child-Pugh Score ICU Mortality 4 (8.9%) 21 (80.7%) < Year Mortality 12 (30%) 24 (92%) <0.001 *Patients with HE, but no acute renal failure or vasopressor use during ICU stay. HE patients with acute renal failure and/or vasopressor use during ICU stay. Fichet J et al. J Crit Care 2009;24:
18 Multivariate Analysis for ICU and 1-Year Mortality of Patients with Severe HE Vasopressor use and acute renal failure were the main independent predictors of ICU death and 1-year mortality Variables Odds ratio ICU Mortality 95% CI p Odds ratio 1-Year Mortality 95% CI Vasopressor Use p Acute Renal Failure or Hepatorenal Syndrome Severity of Acute Illness (SAPSII)* *SAPSII, Simplified Acute Physiology Score Fichet J et al. J Crit Care 2009;24:
19 Comparative Outcome Probabilities for Various Complications of Cirrhosis Complication Survival at 1 year Survival at 3 years Varices (non-bleeding) w/o ascites 1 97% NA Ascites ± varices 1,2 80% 50% Bleeding Varices ± Ascites 1 43% NA Hepatic Encephalopathy 3 42% 23% Projected survival rates 1 year after diagnosis of overt HE are comparable to survival rates of cirrhotic patients with bleeding varices NA=Not Available 1. Adapted from D Amico G et al. J Hepatol 2006;44: Arroyo V, Colmenero J. J Hepatol. 2003;38:S69-S Adapted from Bustamante et al. J Hepatol. 1999;30:
20 Minimal HE Affects Quality of Life in Cirrhotic Patients 30 Cirrhosis With MHE (n=48) Cirrhosis W/O MHE (n=131) Reference Population (n=594) 25 Mean SIP Score* SIP Scales * Sickness Impact Profile (SIP) used to determine influence of chronic disease on patients daily functioning; scores range from 0 (best score) to 100 (worst score). Groeneweg M, et al. Hepatology. 1998;28:45-49.
21 Score HE Affects Health-Related Quality of Life According to Presence and Degree Short Form-36 Questionnaire Results US Norms No HE (n=35) MHE (n=36) OHE (n=89) Physical Functioning Physical Role Bodily Pain Arguedas M et al. Dig Dis Sci 2003;48: General Health Vitality Social Functioning Emotional Role Mental Health Physical Summary Mental Summar y
22 Burden of Cirrhosis and HE: Impact of Cirrhosis-Related Expenses on Daily Life Impact Within Past 3 Years % % 46% 104 patients (70% male, median MELD 12, 44% HCV, 49% veterans) 44% had previous HE (all were on lactulose while 23% had severe previous HE and were on both rifaximin and lactulose) 20 15% 11% 10% 7% 7% 0 Bajaj JS, et al. Am J Gastroenterol 2011;106:
23 Burden of Cirrhosis and HE: Impact of Cirrhosis- Related Medical Expenses on Adherence Impact Within Past Year 50 N= % % 30 26% % 10% 5% 0 Lost insurance Missed appointments Did not take meds Took less than prescribed meds Missed procedures Bajaj JS, et al. Am J Gastroenterol 2011;106:
24 Burden of Cirrhosis and HE: Impact on Ability to Work No Previous HE (n=58) Previous HE (n=46) P value Age (years) MELD score Currently working 81% 12.5% Need to decrease hours 39% 71% Worse off regarding job 47% 74% Worse off financially 61% 85% Median longest period free of work 21 days 365 days Debt from cirrhosis 36% 54% 0.06 Bajaj JS, et al. Am J Gastroenterol 2011;106:
25 Utilization and Outcome of Critical Care in Patients With Cirrhosis Reviewed 2006 Nationwide Inpatient Sample (NIS) of the Health Care Utilization Project to identify hospitalization records with cirrhosis and/or portal hypertensive complications 65,072 discharge records met the inclusion criteria, which projected to 317,300 cirrhosis hospitalizations (95% CI, 300; ,400) Characteristics of patients requiring critical care Mean age: 55.5 years Male: 63% Ascites: 49% Encephalopathy: 41% Variceal bleeding: 14% Hepatorenal syndrome: 12% Kim W, et al. Hepatology. 2010;52(Suppl S1):910A-911A.
26 Utilization and Outcome of Critical Care in Patients With Cirrhosis Increased risk of death and hospital charges associated with complications In-Hospital Death Total Charges Factor Odds Ratio P % Increase P ICU care 13.9 < % <.01 Encephalopathy 2.0 <.01 28% <.01 Hepatorenal syndrome 6.1 <.01 45% <.01 Ascites 1.1 <.01 23% <.01 Variceal hemorrhage 0.8 <.01 36% <.01 HCC 1.5 <.01 9%.08 Kim W, et al. Hepatology. 2010;52(Suppl S1):910A-911A.
27 Current Treatment Options for HE Drug Name Drug Class Indication Lactulose Rifaximin Neomycin Metronidazole Vancomycin Poorly absorbed disaccharide Non-aminoglycoside semi-synthetic, nonsystemic antibiotic Aminoglycoside antibiotic Synthetic antiprotozoal and antibacterial agent Aminoglycoside antibiotic Decrease blood ammonia concentration Prevention and treatment of portal-systemic encephalopathy Reduction in risk of OHE recurrence in patients 18 years of age Adjuvant therapy in hepatic coma Not approved for HE Not approved for HE Adapted from: Advisory Committee/UCM pdf. Accessed 02/17/11; Accessed 02/17/11.
28 Accredited by: Treatment
29 OHE Treatment Goals Acute episode of HE Treatment of precipitating factors Improvement in mental status Evaluation for liver transplant Out-patient management after an episode of HE Prevention of recurrent episodes of HE Improvement of daily functioning Evaluation for liver transplant Bajaj JS. Aliment Pharmacol Ther. 2010;31:
30 Proposed Terminology for Prophylactic Treatment of HE Treating patients with covert HE to prevent development of a first episode is referred to as primary prophylaxis of HE Preventing recurrence of HE in patients who had a previous episode of HE is referred to as secondary prophylaxis of HE Sharma BC et al. Gastroenterology. 2009;137:
31 Secondary Prophylaxis of OHE: Lactulose vs Placebo Open-label randomized controlled trial Consecutive cirrhotic patients who recovered from HE randomized to receive lactulose (n=70) or placebo (n=70) Primary end point was development of OHE Median follow-up of 14 months (range 1-20 months) Sharma BC, et al. Gastroenterology. 2009:137:
32 Probability of hepatic encephalopathy Probability of Developing HE in Patients Receiving Prophylactic Lactulose vs Placebo P= Patients at risk* Follow-up in months Lactulose 61 60(1) 59(2) 58(3) 51(8) 45(9) 38(11) 28(12) 10(12) 7(12) 1(12) Placebo 64 62(1) 59(4) 50(13) 37(24) 33(27)28(27) 19(29) 13(30) 8(30) 4(30) *Values in parentheses indicate the cumulative number of subjects who developed HE. Sharma BC, et al. Gastroenterology. 2009:137:
33 Side Effects in Patients Receiving Prophylactic Lactulose vs Placebo Lactulose (n=61) Placebo (n=64) Diarrhea 14 (23%) --- Abdominal bloating 6 (10%) --- Distaste to lactulose 8 (13%) --- Constipation (16%) All patients could tolerate and remained compliant to lactulose therapy Sharma BC, et al. Gastroenterology. 2009:137:
34 Secondary Prophylaxis of HE: Rifaximin vs Placebo Rifaximin 550 mg BID for 6 mo (n=140) Discontinued n=52 (37%) Breakthrough HE: n=28 Adverse event: n=8 Death: n=6 Patient request: n=6 Exclusion criteria: n=1 Other: n=3 Randomization 1:1 N=299 (Randomized Controlled Trial) Placebo for 6 mo (n=159) Discontinued n=93 (58%) Breakthrough HE: n=69 Patient request: n=9 Adverse event: n=7 Death: n=3 Exclusion criteria: n=3 Other: n=2 Completed Study n=88 Completed Study n=66 Bass NM, et al. N Engl J Med. 2010;362:
35 Rifaximin Treatment in HE: Lactulose Use at Baseline and During Study Rifaximin (n=140) Placebo (n=159) Lactulose use at baseline n (%)* 128 (91.4) 145 (91.2) Lactulose use during study n (%)* 128 (91.4) 145 (91.2) *During the study, 3 patients who had been receiving lactulose discontinued the therapy and another 3 patients started lactulose (1 in the rifaximin group and 2 in the placebo group). Bass NM, et al. N Engl J Med. 2010;362:
36 Patients (%) Rifaximin Treatment in HE: Time to First Breakthrough Episode (Primary End Point) (77.9%) Rifaximin Placebo (54.1%) 20 0 Hazard ratio with rifaximin, 0.42(95% CI, ) P< Days since randomization Bass NM, et al. N Engl J Med. 2010; 362(12):
37 Patients (%) Rifaximin Treatment in HE: Time to First HE-Related Hospitalization (Secondary End Point) (86.4%) Rifaximin 60 Placebo (77.4%) Hazard ratio with rifaximin, 0.50(95% CI, ) P= Days since randomization Bass NM, et al. N Engl J Med. 2010; 362(12):
38 Rifaximin and HE: Side Effects Similar to Placebo The incidences of adverse events did not differ significantly between the two study groups (P>.05 for all comparisons) Adverse Events Reported in 10% of Patients in Either Study Group Event, n (%) Any event Nausea Diarrhea Fatigue Peripheral edema Ascites Dizziness Headache Rifaximin (n=140) 112 (80.0) 20 (14.3) 15 (10.7) 17 (12.1) 21 (15.0) 16 (11.4) 18 (12.9) 14 (10.0) Placebo (n=159) 127 (79.9) 21 (13.2) 21 (13.2) 18 (11.3) 13 (8.2) 15 (9.4) 13 (8.2) 17 (10.7) Bass NM, et al. N Engl J Med. 2010;362:
39 Rifaximin Long Term Efficacy and Safety: Patient Disposition Randomized Controlled Trial (6 months) Rifaximin 550 mg b.i.d. n=140 Open Label Maintenance Continuing Rifaximin 550 mg b.i.d. n=70 RCT N=299 New patients n=170 All Patients OLM N=322 Placebo n=159 Switched from placebo to Rifaximin 550 mg b.i.d. n=82 Concomitant lactulose use was permitted throughout the RCT and OLM trial Mullen KD et al. J Hepatol 2011;54(Suppl 1):S49.
40 Infection Rates Remain Stable During Long-Term Rifaximin Treatment RCT Placebo n=159; PEY=46 Infection Incidence, n (rate*) RCT Rifaximin n=140; PEY=50 All Rifaximin n=392; PEY=510 Any infection 49 (1.32) 46 (1.12) 214 (0.72) Cellulitis 3 (0.066) 3 (0.060) 34 (0.071) C.difficile infection 0 2 (0.040) 6 (0.012) Peritonitis 6 (0.131) 3 (0.060) 22 (0.044) Pneumonia 1 (0.022) 4 (0.080) 42 (0.084) Sepsis/Septic shock Urinary tract/ kidney 5 (0.109) 2 (0.040) 31 (0.062) 14 (0.320) 9 (0.187) 83 (0.193) *Rate = number of subjects/person exposure years (PEY) All rifaximin = rifaximin treated patients from both randomized controlled trial (RCT) and open label maintenance trial Sanyal A et al. J Hepatol 2012;56(Suppl 2):S255-S256.
41 Complications Seen During Long-Term Administration of Rifaximin Patients were followed for up to 5 years, death, or liver transplantation Rifaximin (n=23) Controls (n=46) P value Variceal bleeding (%) P=.011 Hepatic encephalopathy (%) P=.034 Spontaneous bacterial peritonitis (%) P=.027 Hepatorenal syndrome (%) P=.037 Death 7 / 23 (30.4%) 24 / 46 (52.2%) -- 5-year cumulative probability of survival (%) P=.012 Vlachogiannakos J, et al. Hepatology. 2010:52(Suppl S1):328A-329A.
42 Primary Prophylactic Therapy: MHE Treatment Goals Goals of primary prophylactic therapy Delay progression to overt HE Improve quality of life Maintain employment status Preserve driving privilege Prakash R, Mullen KD. Nat Rev Gastroenterol Hepatol. 2010;7:
43 Lactulose for Primary Prophylaxis of Overt HE in Cirrhotic Patients: Results Median follow-up 12 months P= % 60% Lactulose No Lactulose % of Patients / 60 36/ 60 MHE at Baseline P= % 6/ 55 30% Developed OHE 9% 15/ 50 5/55 P=0.16 Died 20% 10/ 50 Sharma BC et al. J Hepatol 2012;56(Suppl 2):S238.
44 Lactulose Improves Health-related QoL in Patients With MHE 25 0 months 3 months 20 Score Prasad S, et al. Hepatology. 2007;45:
45 Rifaximin vs Placebo: Reversal of MHE Placebo (n=45) Rifaximin (n=49) P<.0001 Patients Showing Reversal of MHE (%) P<.0001 Duration of Treatment Sidhu S, et al. Am J Gastroenterol. 2011;106:
46 Rifaximin Improves Health-related QoL in Patients With MHE 20 P=.002 Baseline (n=42) 8 Weeks (n=37) Mean SIP Score P= P=.007 P=.050 P=.00 0 Total Psych Total Physical Sleep/Rest Work Home Mgmt Rec/Pastimes Eating Total SIP Sidhu S, et al. Am J Gastroenterol. 2011;106:
47 Rifaximin Improves Driving Simulator Performance: Methods Minimal HE patients were diagnosed using a cognitive battery of 5 tests All who were current car drivers without overt HE were included in an 8-week trial Trial involved at baseline Driving and navigation simulation Quality of life and Sickness Impact Profile Ammonia MELD score Patients were randomized to rifaximin 550 mg or placebo BID All tests repeated on the 8-week visit Bajaj JS, et al. Gastroenterology 2011;140:
48 Rifaximin Improves Driving Simulator Performance: Results Rifaximin (n=21) Placebo (n=21) P value Improved cognitive tests 91% 61%.02 Reduced total driving errors 76% 33%.013 Reduced speeding tickets 81% 33%.005 Reduced illegal turns 62% 19%.012 Reduced collisions 43% 33%.751 Bajaj JS, et al. Gastroenterology 2011;140:
49 Reversibility of HE Traditional concept: Most OHE events are potentially reversible Only those patients who succumb to the precipitating event (i.e., bleeding, infection) are not reversible Patients who regain consciousness and survive a severe HE event typically seem to return to their baseline level of cognitive functioning with supportive care, or with disaccharides, or with rifaximin A subset of patients with OHE continue to suffer with symptoms and are classified as chronic persistent HE that may not be reversible with medical therapy Neuropathologic characteristics found in brains of patients with HE at autopsy suggest that the concept of complete reversibility requires more in-depth analysis Frederick RT. Clin Liver Dis 2012;16:
50 Psychometric Test Results Before and After Development of First Episode of OHE Patients tested before and after first episode of OHE (n=15) Pre-OHE Post-OHE p-value MELD score (median) Number connection test-a (sec) Number connection test-b (sec) Digit symbol test (points) Block design test (points) ICT targets (% correct) ICT lures (# responded to) ICT lures (first half: runs I-III) ICT lures (second half: runs IV-VI) 4 4* *p= in the first half compared with the second half indicating successful learning Bajaj JS et al. Gastroenterology 2010;138:
51 Persistence of Cognitive Impairment after OHE: Results Prior OHE No OHE P value NCT-A NCT-B DST < LTT time LTT errors SDT BDT < Lures Weighted lures Targets 77% 92% N=163 Bajaj JS et al. J Hepatol 2012;56(Suppl 2):S242.
52 Persistence of Cognitive Impairment after OHE: Results No OHE Prior OHE 1 st Half 2 nd Half 1 st Half 2 nd Half Lures * Weighted lures * Targets (%) * Patients without prior OHE improved significantly on ICT from 1 st to 2 nd half, but those with prior OHE could not improve their performance indicating poor learning capability and persistent cognitive dysfunction *P< on paired t-test Bajaj JS et al. J Hepatol 2012;56(Suppl 2):S242.
53 Impact of Preoperative OHE on Neurocognitive Function after Liver Transplantation Neurocognitive abnormalities were more severe in liver transplant recipients that had suffered from OHE prior to OLT Domains OHE-PreLT (n=25) PHES Results No OHE-PreLT (n=14) Controls (n=20) NCT-A (seconds) * NCT-B (seconds) * Digit symbol (points) * ǂ Serial dotting (seconds) Line tracing (seconds) Line tracing (errors) *p<0.001 vs. controls; p<0.01 vs. No HE-PreLT; ǂ p<0.05 vs. No HE-PreLT. Sotil EU et al. Liver Transpl 2009;15:
54 Conclusions The incidence of cirrhosis is increasing and the incidence of hepatic encephalopathy parallels the increase in cirrhosis HE has a negative impact on a cirrhotic patient s quality of life Patients diagnosed with covert HE have a high probability of experiencing an overt HE episode Primary prophylactic treatment of covert HE patients with either lactulose or rifaximin is effective in preventing overt HE
55 Conclusions (cont) Overt HE is associated with a poor prognosis Survival is <50% at one year, similar to survival of patients with bleeding varices Secondary prophylactic treatment following an overt HE episode with either lactulose or rifaximin is effective in preventing a recurrent episode of overt HE Recent evidence suggests that cognitive impairment associated with overt HE may not be completely reversible
56 Accredited by: Post Test
57 Accredited by: General Discussion Q & A
58 Thank you for supporting this program For additional CME offerings, please visit
The Importance of Diagnosing Covert Hepatic Encephalopathy
The Importance of Diagnosing Covert Hepatic Encephalopathy Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council
More informationTreatment of Overt Hepatic Encephalopathy: Focus on Outpatient Management
Treatment of Overt Hepatic Encephalopathy: Focus on Outpatient Management Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation
More informationProgram Disclosure. This program is supported by an educational grant from Salix Pharmaceuticals.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the sponsorship
More informationManagement of Hepatic Encephalopathy
Management of Hepatic Encephalopathy Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Disclosure 1. The speaker Atif Zaman, MD MPH
More informationThe Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present:
The Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present: Certified by: Provided by: Endorsed by: Hepatic Encephalopathy Hepatic Encephalopathy:
More informationManagement of Cirrhosis Related Complications
Management of Cirrhosis Related Complications Ke-Qin Hu, MD, FAASLD Professor of Clinical Medicine Director of Hepatology University of California, Irvine Disclosure I have no disclosure related to this
More informationProgram Disclosure. A maximum of 1.5 contact hours may be earned for successful completion of this activity.
Program Disclosure This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through
More informationThis educational website is funded by a grant from Norgine. Norgine has no responsibility for content or conduct of this website.
Date of preparation: February 2014. 4C/NIPV/0517 1 This educational website is funded by a grant from Norgine. Norgine has no responsibility for content or conduct of this website. 2 Disclaimer This educational
More informationCauses of Liver Disease in US
Learning Objectives Updates in Outpatient Cirrhosis Management Jennifer Guy, MD MAS Director, Liver Cancer Program California Pacific Medical Center guyj@sutterhealth.org Review cirrhosis epidemiology,
More informationCIRRHOSIS Definition
Cirrhosis Update Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of Gastroenterology & Hepatology Weill Cornell Medical College CIRRHOSIS Definition Irreversible fibrous
More informationNational Institute for Health and Clinical Excellence. Single Technology Appraisal (STA)
Comment 2: the draft scope Appendix D NICE s response to consultee and commentator comments on the draft scope and provisional matrix National Institute for Health and Clinical Excellence Single Technology
More informationThe University Hospitals and Clinics The University of Mississippi Medical Center Jackson, Mississippi
The University Hospitals and Clinics The University of Mississippi Medical Center Jackson, Mississippi Pharmacy and Therapeutics Committee Drug Evaluation (Xifaxan ) June 2012 Generic Name Brand Name Xifaxan
More informationDiagnosis and Management of Hepatic Encephalopathy
Diagnosis and Management of Hepatic Encephalopathy Fred Poordad, MD VP, Academic and Clinical Affairs The Texas Liver Institute Professor of Medicine University of Texas Health Science Center San Antonio,
More informationStrategies for Improving Long-term Management of Hepatic Encephalopathy: Assessing Therapies for Secondary Prophylaxis
Strategies for Improving Long-term Management of Hepatic Encephalopathy: Assessing Therapies for Secondary Prophylaxis Sponsored by Integrity Continuing Education, Inc. Supported by an educational Practitioner
More informationA Simplified Psychometric Evaluation for the Diagnosis of Minimal Hepatic Encephalopathy
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:613 616 A Simplified Psychometric Evaluation for the Diagnosis of Minimal Hepatic Encephalopathy OLIVIERO RIGGIO,* LORENZO RIDOLA,* CHIARA PASQUALE,* ILARIA
More informationFaculty Affiliation. Faculty Disclosures. Alpesh Amin, MD, has no real or apparent conflicts of interest to report.
Strategies for Improving Long-term Management of Hepatic Encephalopathy: Assessing Therapies for Secondary Prophylaxis Sponsored by Integrity Continuing Education, Inc. Supported by an educational Practitioner
More informationFaculty Affiliation. Faculty Disclosures. Learning Objectives. Impact of HE on HRQOL. Overview of HE
Faculty Affiliation Strategies for Improving Long-term Management of Hepatic Encephalopathy: Assessing Therapies for Secondary Prophylaxis Alpesh Amin, MD Executive Director Hospitalist Program Professor
More informationTreating patients with end-stage liver disease: Are we ready? Dr. Mino R. Mitri, M.D., C.M., M.Ed., FRCPC
Treating patients with end-stage liver disease: Are we ready? Dr. Mino R. Mitri, M.D., C.M., M.Ed., FRCPC mino.mitri@ubc.ca No Conflict of Interest 157 patients 157 patients 6 transplanted Criteria Liver
More informationStrategies for Improving Long-term Management of Hepatic Encephalopathy: Assessing Therapies for Secondary Prophylaxis
Strategies for Improving Long-term Management of Hepatic Encephalopathy: Assessing Therapies for Secondary Prophylaxis Sponsored by Integrity Continuing Education, Inc. Supported by an educational Practitioner
More informationWhat s New in the Management of Hepatic Encephalopathy?
What s New in the Management of Hepatic Encephalopathy? Jasmohan S Bajaj, MD Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University and McGuire VA Medical Center, Richmond,
More informationHepatic Encephalopathy Update: Reports from the 64th Annual Meeting of the American Association for the Study of Liver Diseases
Hepatic Encephalopathy Update: Reports from the 64th Annual Meeting of the American Association for the Study of Liver Diseases Credit Designation Purdue University College of Pharmacy designates this
More informationCognitive abnormalities in cirrhosis
AISF 2015 - Young Investigator Lecture Cognitive abnormalities in cirrhosis Sara Montagnese Disclosures I have received lecture fees from Merz Pharmaceuticals GmbH and Norgine The University of Padova
More informationManagement of the Cirrhotic Patient in the ICU
Management of the Cirrhotic Patient in the ICU Peter E. Morris, MD Professor & Chief, Pulmonary, Critical Care and Sleep Medicine University of Kentucky Conflict of Interest Funding US National Institutes
More informationHepatic Encephalopathy
Hepatic Encephalopathy John Barber UMassMedical Student, Class of 2019 www.12daysinmarch.com Outline Overview Normal Physiology Pathology Symptoms Diagnosis Treatment Overview Ammonia (NH 3 ) is a byproduct
More informationMANAGEMENT OF LIVER CIRRHOSIS: PRACTICE ESSENTIALS AND PATIENT SELF-MANAGEMENT
MANAGEMENT OF LIVER CIRRHOSIS: PRACTICE ESSENTIALS AND PATIENT SELF-MANAGEMENT Sherona Bau, ACNP The Pfleger Liver Institute 200 UCLA Medical Plaza, Suite 214 Los Angeles, CA 90095 September 30, 2017 I
More informationPALLIATIVE CARE IN END-STAGE LIVER DISEASE
PALLIATIVE CARE IN END-STAGE LIVER DISEASE Ken S. Ota, DO Family Medicine Banner Good Samaritan Medical Center Learning Objectives: Describe the common bio-psycho-social issues in end-stage liver disease
More informationAnalysis of combined effect of synbiotic and LOLA in improving neuropsychometric function
2017; 6(5): 152-156 ISSN (E): 2277-7695 ISSN (P): 2349-8242 NAAS Rating 2017: 5.03 TPI 2017; 6(5): 152-156 2017 TPI www.thepharmajournal.com Received: 26-03-2017 Accepted: 27-04-2017 Preetha Nandabalan
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Accelerated intravascular coagulation and fibrinolysis (AICF) in liver disease, 390 391 Acid suppression in liver disease, 403 404 ACLF.
More informationCOMPLICATIONS OF CIRRHOSIS: ASCITES & HEPATIC ENCEPHALOPATHY
COMPLICATIONS OF CIRRHOSIS: ASCITES & HEPATIC ENCEPHALOPATHY DR. ESTER YAGUDAYEVA CLINICAL PHARMACIST HOSPICE PHARMACY SOLUTIONS OBJECTIVES Understand the prognosis of End Stage Liver Disease (ESLD) Identify
More informationHepatic Encephalopathy Update:
Hepatic Encephalopathy Update: Reports From the American Association for the Study of Liver Diseases Annual Meeting, 2011 Project ID: 11-0014-NL-4 Credit Designation Hepatic encephalopathy (HE) is a largely
More informationManagement of Cirrhotic Complications Uncontrolled Ascites. Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University
Management of Cirrhotic Complications Uncontrolled Ascites Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University Topic Definition, pathogenesis Current therapeutic options Experimental treatments
More informationInnovative Therapeutics for Orphan Liver Disease
Innovative Therapeutics for Orphan Liver Disease Note Regarding Forward-Looking Statements Certain statements in this presentation constitute forward-looking statements within the meaning of the Securities
More informationDecompensated chronic liver disease
Decompensated chronic liver disease Definition of decompensated chronic liver disease Patients with chronic liver disease can present with acute decompensation due to various causes. The decompensation
More informationBeta-blockers in cirrhosis: Cons
Beta-blockers in cirrhosis: Cons Eric Trépo MD, PhD Dept. of Gastroenterology. Hepatopancreatology and Digestive Oncology. C.U.B. Hôpital Erasme. Université Libre de Bruxelles. Bruxelles. Belgium Laboratory
More informationManaging Encephalopathy in the Outpatient Setting
REVIEW Managing Encephalopathy in the Outpatient Setting Sahaj Rathi, M.D., and Radha K. Dhiman, M.D., D.M., F.A.M.S., F.A.C.G., F.R.C.P., F.A.A.S.L.D. Hepatic encephalopathy (HE) refers to brain dysfunction
More informationOptimizing Outcomes of Patients Hospitalized for Hepatic Encephalopathy: Focus on Early Intervention and Transitional Care
Optimizing Outcomes of Patients Hospitalized for Hepatic Encephalopathy: Focus on Early Intervention and Transitional Care This CME activity is provided by Integrity Continuing Education. This CEU/CNE
More informationInhibitory Control Test for the Diagnosis of Minimal Hepatic Encephalopathy
GASTROENTEROLOGY 2008;135:1591 1600 Inhibitory Control Test for the Diagnosis of Minimal Hepatic Encephalopathy JASMOHAN S. BAJAJ,* MUHAMMAD HAFEEZULLAH, JOSE FRANCO, RAJIV R. VARMA, RAYMOND G. HOFFMANN,
More informationHepatic encephalopathy (HE) is a neuropsychiatric
Considerations for the Cost-Effective Management of Hepatic Encephalopathy Steven L. Flamm, MD Hepatic encephalopathy (HE) is a neuropsychiatric condition that is usually associated with acute or chronic
More informationHepatic Encephalopathy Update: Reports from the 2013 International Liver Conference
Reports from the 2013 International Liver Conference Credit Designation Purdue University College of Pharmacy designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s). Physicians
More informationA Randomized, Double-Blind, Controlled Trial Comparing Rifaximin Plus Lactulose With Lactulose Alone in Treatment of Overt Hepatic Encephalopathy
1458 ORIGINAL CONTRIBUTIONS nature publishing group see related editorial on page x A Randomized, Double-Blind, Controlled Trial Comparing Rifaximin Plus Lactulose With Lactulose Alone in Treatment of
More informationThe usefulness of critical flicker frequency in the diagnosis and follow-up of covert hepatic encephalopathy treated with Rifaximin-α
Human & Veterinary Medicine International Journal of the Bioflux Society OPEN ACCESS Research Article The usefulness of critical flicker frequency in the diagnosis and follow-up of covert hepatic encephalopathy
More informationOrgan allocation for liver transplantation: Is MELD the answer? North American experience
Organ allocation for liver transplantation: Is MELD the answer? North American experience Douglas M. Heuman, MD Virginia Commonwealth University Richmond, VA, USA March 1998: US Department of Health and
More informationNorepinephrine versus Terlipressin for the Treatment of Hepatorenal Syndrome
Norepinephrine versus Terlipressin for the Treatment of Hepatorenal Syndrome Disclosure I have no conflicts of interest to disclose Name: Margarita Taburyanskaya Title: PharmD, PGY1 Pharmacy Practice Resident
More informationAscites Management. Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology
Ascites Management Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Disclosure 1. The speaker Atif Zaman, MD MPH have no relevant
More informationMinimal and overt hepatic encephalopathy are constituents
GASTROENTEROLOGY 2010;138:2332 2340 Persistence of Cognitive Impairment After Resolution of Overt Hepatic Encephalopathy JASMOHAN S. BAJAJ,*, CHRISTINE M. SCHUBERT, DOUGLAS M. HEUMAN,* JAMES B. WADE, DOUGLAS
More informationManagement of overt hepatic encephalopathy: a focus on rifaximin-α and NICE TA337
cpd credits summarising clinical guidelines for primary care Guidance Update www. Management of overt hepatic encephalopathy: a focus on rifaximin-α and NICE TA337 This Guidelines supplement has been commissioned
More informationBETA-BLOCKERS IN CIRRHOSIS.PRO.
BETA-BLOCKERS IN CIRRHOSIS.PRO. Angela Puente Sánchez. MD PhD Hepatology Unit. Gastroenterology department Marques de Valdecilla University Hospital. Santander INTRODUCTION. Natural history of cirrhosis
More informationEsophageal Varices Beta-Blockers or Band Ligation. Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph
Esophageal Varices Beta-Blockers or Band Ligation Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph Esophageal Varices Beta-Blockers or Band Ligation? Risk of esophageal variceal
More informationComplications of Cirrhosis
Complications of Cirrhosis Causes of Cirrhosis Alcohol Chronic Viral Hepatitis (B/C) Haemochromatosis Autoimmune Hepatitis NAFLD/NASH Primary Biliary Cirrhosis Primary Sclerosing Cholangitis 1-AT deficiency
More informationSteps in Assessing Fibrosis 4/30/2015. Overview of Liver Disease Associated With HCV
Overview of Liver Disease Associated With HCV Marion G. Peters, MD John V. Carbone, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco San Francisco,
More informationChronic Hepatic Disease
Chronic Hepatic Disease 10 th Leading Cause of Death Liver Functions Energy Metabolism Protein Synthesis Solubilization, Transport, and Storage Protects and Clears drugs, damaged cells Causes of Liver
More informationCritical flicker frequency test for diagnosing minimal hepatic encephalopathy in patients with cirrhosis
Turk J Gastroenterol 2017; 28: 191-6 Liver Critical flicker frequency test for diagnosing minimal hepatic encephalopathy in patients with cirrhosis Banu Demet Özel Coşkun 1, Mustafa Özen 2 1 Clinic of
More informationEvaluating HIV Patient for Liver Transplantation. Marion G. Peters, MD Professor of Medicine University of California San Francisco USA
Evaluating HIV Patient for Liver Transplantation Marion G. Peters, MD Professor of Medicine University of California San Francisco USA Slide 2 ESLD and HIV Liver disease has become a major cause of death
More informationLiver failure &portal hypertension
Liver failure &portal hypertension Objectives: by the end of this lecture each student should be able to : Diagnose liver failure (acute or chronic) List the causes of acute liver failure Diagnose and
More informationIJBCP International Journal of Basic & Clinical Pharmacology
Print ISSN: 2319-2003 Online ISSN: 2279-0780 IJBCP International Journal of Basic & Clinical Pharmacology DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20170331 Original Research Article Effectiveness
More informationIn-Hospital Mortality and Economic Burden Associated With Hepatic Encephalopathy in the United States From 2005 to 2009
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:1034 1041 In-Hospital Mortality and Economic Burden Associated With Hepatic Encephalopathy in the United States From 2005 to 2009 MARIA STEPANOVA, ALITA
More informationMELD score and antibiotics use are predictors of length of stay in patients hospitalized with hepatic encephalopathy
Martel-Laferrière et al. BMC Gastroenterology 2014, 14:185 RESEARCH ARTICLE Open Access MELD score and antibiotics use are predictors of length of stay in patients hospitalized with hepatic encephalopathy
More informationCLINICAL How Should a Hospitalized Patient with Newly Diagnosed Cirrhosis Be Evaluated and Managed?
CLINICAL How Should a Hospitalized Patient with Newly Diagnosed Cirrhosis Be Evaluated and Managed? The Hospitalist. 2016 August;2016(8) Author(s): Raj Sehgal, MD; Joshua Hanson, MD, MPH; Division OF The
More informationManagement of Acute Decompensation of Cirrhosis JOHN O GRADY KING S COLLEGE HOSPITAL
Management of Acute Decompensation of Cirrhosis JOHN O GRADY KING S COLLEGE HOSPITAL Terminology Acute decompensation of cirrhosis - stable patient with sudden deterioration Acute-on-chronic liver failure
More informationEuropean. Young Hepatologists Workshop. Organized by : Quantification of fibrosis and cirrhosis outcomes
supported by from Gilea Quantification of fibrosis and cirrhosis outcomes th 5 European 5 European Young Hepatologists Workshop Young Hepatologists Workshop August, 27-29. 2015, Moulin de Vernègues Vincenza
More informationElectroencephalography Versus Psychometric Tests in Diagnosis of Minimal Hepatic Encephalopathy
Elmer ress Original Article J Neurol Res. 2016;6(4):65-71 Electroencephalography Versus Psychometric Tests in Diagnosis of Minimal Hepatic Encephalopathy Aktham Ismail Alemam a, b, Mohamed Ahmad Shaaban
More informationComplex neuropsychatric syndrome complicating advanced liver disease and/or portosystemic shunting (1990s) Complex neuropsychatric syndrome caused by
Complex neuropsychatric syndrome complicating advanced liver disease and/or portosystemic shunting (1990s) Complex neuropsychatric syndrome caused by portosystemic venous shunting with or without intrinsic
More informationCHAPTER 1. Alcoholic Liver Disease
CHAPTER 1 Alcoholic Liver Disease Major Lesions of Alcoholic Liver Disease Alcoholic fatty liver - >90% of binge and chronic drinkers Alcoholic hepatitis precursor of cirrhosis Alcoholic cirrhosis end
More informationPatients With Minimal Hepatic Encephalopathy Have Poor Insight Into Their Driving Skills
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6:1135 1139 Patients With Minimal Hepatic Encephalopathy Have Poor Insight Into Their Driving Skills JASMOHAN S. BAJAJ,* KIA SAEIAN, MUHAMMAD HAFEEZULLAH,
More informationManagement of Ascites and Hepatorenal Syndrome. Florence Wong University of Toronto. June 4, /16/ Gore & Associates: Consultancy
Management of Ascites and Hepatorenal Syndrome Florence Wong University of Toronto June 4, 2016 6/16/2016 1 Disclosures Gore & Associates: Consultancy Sequana Medical: Research Funding Mallinckrodt Pharmaceutical:
More informationComplications Requiring Hospital Admission and Causes of In-Hospital Death over Time in Alcoholic and Nonalcoholic Cirrhosis Patients
Gut and Liver, Vol. 10, No. 1, January 2016, pp. 95-100 ORiginal Article Complications Requiring Hospital Admission and Causes of In-Hospital Death over Time in and Cirrhosis Patients Hee Yeon Kim, Chang
More informationInfections In Cirrhotic patients. Dr Abid Suddle Institute of Liver Studies King s College Hospital
Infections In Cirrhotic patients Dr Abid Suddle Institute of Liver Studies King s College Hospital Infection in cirrhotic patients Leading cause morbidity/mortality Common: 30-40% of hospitalised cirrhotic
More informationGI bleeding in chronic liver disease
GI bleeding in chronic liver disease Stuart McPherson Consultant Hepatologist Liver Unit, Freeman Hospital, Newcastle upon Tyne and Institute of Cellular Medicine, Newcastle University. Case 54 year old
More informationCirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association
CIRRHOSIS AND PORTAL HYPERTENSION Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association WHAT IS CIRRHOSIS? What is Cirrhosis? DEFINITION OF CIRRHOSIS
More informationThe Yellow Patient. Dr Chiradeep Raychaudhuri, Consultant Hepatologist, Hull University Teaching Hospitals NHS Trust
The Yellow Patient Dr Chiradeep Raychaudhuri, Consultant Hepatologist, Hull University Teaching Hospitals NHS Trust there s a yellow patient in bed 40. It s one of yours. Liver Cirrhosis Why.When.What.etc.
More informationHEPATIC ENCEPHALOPATHY(HE) AND NUTRITIONAL SUPPORT. Jin-Woo Lee, MD,PhD. Division of Hepatology Inha University Hospital
HEPATIC ENCEPHALOPATHY(HE) AND NUTRITIONAL SUPPORT Jin-Woo Lee, MD,PhD. Division of Hepatology Inha University Hospital Contents 1. Definition and causes of HE 2. Diagnosis and treatment of HE 3. Malnutriton
More informationThe Management of Ascites & Hepatorenal Syndrome. Florence Wong University of Toronto. Falk Symposium March 14, 2008
The Management of Ascites & Hepatorenal Syndrome Florence Wong University of Toronto Falk Symposium March 14, 2008 Management of Ascites Sodium Restriction Mandatory at all stages of ascites in order to
More informationEDUCATION PRACTICE. Management of Refractory Ascites. Clinical Scenario. The Problem
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:1187 1191 EDUCATION PRACTICE Management of Refractory Ascites ANDRÉS CÁRDENAS and PERE GINÈS Liver Unit, Institute of Digestive Diseases, Hospital Clínic,
More informationManagement of HepatoCellular Carcinoma
9th Symposium GIC St Louis - 2010 Management of HepatoCellular Carcinoma Overview Pierre A. Clavien, MD, PhD Department of Surgery University Hospital Zurich Zurich, Switzerland Hepatocellular carcinoma
More informationManagement of Chronic Liver Failure/Cirrhosis Complications in Hospitals. By: Dr. Kevin Dolehide
Management of Chronic Liver Failure/Cirrhosis Complications in Hospitals By: Dr. Kevin Dolehide Overview DX Cirrhosis and Prognosis Compensated Decompensated Complications Of Cirrhosis Management Of Complications
More informationThe burden of minimal hepatic encephalopathy: from diagnosis to therapeutic strategies
INVITED REVIEW Annals of Gastroenterology (2018) 31, 1-14 The burden of minimal hepatic encephalopathy: from diagnosis to therapeutic strategies Lorenzo Ridola a, Vincenzo Cardinale a, Oliviero Riggio
More informationSupplemental Appendix. 1. Protocol Definition of Sustained Virologic Response. A patient has a sustained virologic response if:
Supplemental Appendix 1. Protocol Definition of Sustained Virologic Response A patient has a sustained virologic response if: 1. The patient is a responder at the end of treatment and all subsequent planned
More informationConflict of Interest and Disclosures of Relevant Financial Relationships
Management of Hepatic Encephalopathy in Hospice and Palliative Care ProCare HospiceCare Lunch and Learn Series Brett Gillis, PharmD, RPh Conflict of Interest and Disclosures of Relevant Financial Relationships
More informationKing s College Hospital NHS Foundation Trust. Acute on Chronic Liver Failure: Practical management outside the tertiary centre.
King s College Hospital NHS Foundation Trust NHS Acute on Chronic Liver Failure: Practical management outside the tertiary centre. William Bernal Professor of Liver Critical Care Liver Intensive Therapy
More informationfollowing the last documented transfusion; thereafter, evaluate the residual impairment(s).
Adult Listings 5.01 Category of Impairments, Digestive System 5.02 Gastrointestinal hemorrhaging from any cause, requiring blood transfusion (with or without hospitalization) of at least 2 units of blood
More informationIn- and exclusion criteria
In- and exclusion criteria Kerstin Schütte Department of Gastroenterology, Hepatology and Infectious Diseases University of Magdeburg Overview: Study population Inclusion criteria I - General criteria
More informationLiver Transplantation: The End of the Road in Chronic Hepatitis C Infection
University of Massachusetts Medical School escholarship@umms UMass Center for Clinical and Translational Science Research Retreat 2012 UMass Center for Clinical and Translational Science Research Retreat
More informationDenver Shunts vs TIPS for Ascites
Denver Shunts vs TIPS for Ascites Hooman Yarmohammadi MD Assistant Professor of Radiology Interventional Radiology & Image Guided Therapies Memorial Sloan-Kettering Cancer Center, New York, USA Hooman
More informationLiver Failure. The most severe clinical consequence of liver disease is liver failure:
Liver diseases I The major primary diseases of the liver are: - Viral hepatitis, - Nonalcoholic fatty liver disease (NAFLD), - Alcoholic liver disease, - Hepatocellular carcinoma (HCC) Hepatic damage also
More informationCare of the Patient With Cirrhosis
REVIEW Care of the Patient With Cirrhosis Anitha Yadav, M.D., and Hugo E. Vargas, M.D. Caring for patients with cirrhosis involves multidisciplinary and timely management of several complications while
More informationControversies in Management of Portal Hypertension and Cirrhosis Complications in the Transplant Candidate
Controversies in Management of Portal Hypertension and Cirrhosis Complications in the Transplant Candidate Patrick Northup, MD, FAASLD, FACG Medical Director, Liver Transplantation University of Virginia
More informationRenal Care and Liver Disease: Disease Trajectory and Hospice Eligibility
Renal Care and Liver Disease: Disease Trajectory and Hospice Eligibility Terri L. Maxwell PhD, APRN VP, Strategic Initiatives Weatherbee Resources/HEN Course Materials & Disclosure Course materials including
More informationInitial approach to ascites
Ascites: Filling and Draining the Water Balloon Common Pathogenesis in Refractory Ascites, Hyponatremia, and Cirrhosis intrahepatic resistance sinusoidal portal hypertension Splanchnic vasodilation (effective
More informationThe Impact of Chronic Liver Disease on Postoperative Outcomes and Resource Utilization within the National Surgical Quality Improvement Database
The Impact of Chronic Liver Disease on Postoperative Outcomes and Resource Utilization within the National Surgical Quality Improvement Database Joseph B. Oliver, MD MPH, Amy L. Davidow, PhD, Kimberly
More informationPACT module Acute hepatic failure. Intensive Care Training Program Radboud University Medical Centre Nijmegen
PACT module Acute hepatic failure Intensive Care Training Program Radboud University Medical Centre Nijmegen Acute Liver Failure Acute on Chronic Liver Failure Acute loss of hepatocellular function in
More informationCirrhosis with ascites: Is the presence of hemorrhagic ascites an indicator of poor prognosis?
Cirrhosis with : Is the presence of hemorrhagic an indicator of poor prognosis? LIVER Hakan Yıldız, Meral Akdoğan, Nuretdin Suna, Erkin Öztaş, Ufuk B. Kuzu, Zülfükar Bilge, Onur Aydınlı, İsmail Taşkıran
More informationLife After SVR for Cirrhotic HCV
Life After SVR for Cirrhotic HCV KIM NEWNHAM MN, NP CIRRHOSIS CARE CLINIC UNIVERSITY OF ALBERTA Objectives To review the benefits of HCV clearance in cirrhotic patients To review some of the emerging data
More informationLIVER CIRRHOSIS. The liver extracts nutrients from the blood and processes them for later use.
LIVER CIRRHOSIS William Sanchez, M.D. & Jayant A. Talwalkar, M.D., M.P.H. Advanced Liver Disease Study Group Miles and Shirley Fiterman Center for Digestive Diseases Mayo College of Medicine Rochester,
More informationLiver Transplantation Evaluation: Objectives
Liver Transplantation Evaluation: Essential Work-Up Curtis K. Argo, MD, MS VGS/ACG Regional Postgraduate Course Williamsburg, VA September 13, 2015 Objectives Discuss determining readiness for transplantation
More informationOCALIVA (obeticholic acid) oral tablet
OCALIVA (obeticholic acid) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationAmmonia level at admission predicts in-hospital mortality for patients with alcoholic hepatitis
Gastroenterology Report, 5(3), 2017, 232 236 doi: 10.1093/gastro/gow010 Advance Access Publication Date: 1 May 2016 Original article ORIGINAL ARTICLE Ammonia level at admission predicts in-hospital mortality
More informationJMSCR Vol 05 Issue 11 Page November 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 71.58 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i11.33 Prevalence of Hyponatremia among patients
More informationThe Association Between the Serum Sodium Level and the Severity of Complications in Liver Cirrhosis
ORIGINAL ARTICLE DOI: 10.3904/kjim.2009.24.2.106 The Association Between the Serum Sodium Level and the Severity of Complications in Liver Cirrhosis Jong Hoon Kim, June Sung Lee, Seuk Hyun Lee, Won Ki
More information